Wider use of continuous glucose monitoring (CGM), glycemic management during cancer treatment, and individualized dosing of obesity drugs in people with diabetes are just a few of the new topics and ...
The 2026 ADA Standards of Care really further elaborate on the benefits of incretin-based therapies. I can't go through in great detail all of the different roles that incretin-based therapies now ...
Hemoglobin A1c (HbA1c) remains a cornerstone in the diagnosis and monitoring of diabetes, and its proper use is central to implementing the 2023 American Diabetes Association (ADA) guidelines. While ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results